We aimed to evaluate the efficacy and safety of oxaliplatin , 5-fluorouracil ( 5-FU ) , and leucovorin ( LV ) ( FOLFOX-4 ) as second-line treatment in patients with advanced biliary tract cancer ( BTC ) failing gemcitabine/cisplatin first-line chemotherapy .
